​Finding new ways to incentivize and reward drug development for particular therapeutic needs is all the rage these days.  Over the past few years we’ve seen several new incentives incorporated (and proposed for incorporation) into the FDC Act.  These new incentives are quite different from the standard grants of patent and non-patent marketing exclusivities, including incentives that merely stack exclusivity periods upon one another, such as 6-month pediatric exclusivity (FDC Act § 505A) or 5-year Generating Antibiotic Incentives Now Act exclusivity (FDC Act § 505E) or other proposals under consideration (see our previous posts here and here).  

U.S. Senators Bill Cassidy, M.D. (R-LA) and Bob Casey (D-PA) introduced the Promoting Life Saving New Therapies for Neonates Act of 2015 to increase the amount of life-saving treatments available for at risk newborns. This legislation looks to spur innovation for new neonatal drug therapies, improve outcomes for devastating neonatal conditions and give our most vulnerable children the chance to become healthy.